Interleukin-1 beta: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs)
No edit summary
No edit summary
Line 1: Line 1:
<StructureSection load='' size='350' side='right' scene='57/571319/Scene1/1' caption='HUMAN INTERLEUKIN-1 β (PDB code [[9ilb]])'>
== Interleukin-1 beta(IL-1β) ==
== Interleukin-1 beta(IL-1β) ==
<Structure load='9ilb' size='400' frame='true' align='right' caption='HUMAN INTERLEUKIN-1 β (PDB code [[9ilb]])' scene='57/571319/Scene1/1' />
IL-1β along with IL-1α cytokines secreted from local inflammatory cells, are belong to IL-1 family.[1]  The former is dominate (90% of Interleukin-1) and the two cytokines could be distinguished by the cells with which they interact.  IL-1β precursor(31KDa) need to be activated  by protease (convertase or IL-1β converting enzyme[2])  to form IL-1 active species(17KDa)[3].  The active mature IL-1 cytokines could mediate a large range of biological activities such as innate and adaptive immunity as well as bio-components of the acute phase reaction, including the febrile response, secretion of adrenocorticotropic hormone (ACIH), and the synthesis of [http://en.wikipedia.org/wiki/Acute-phase_protein acute phase proteins].
IL-1β along with IL-1α cytokines secreted from local inflammatory cells, are belong to IL-1 family.[1]  The former is dominate (90% of Interleukin-1) and the two cytokines could be distinguished by the cells with which they interact.  IL-1β precursor(31KDa) need to be activated  by protease (convertase or IL-1β converting enzyme[2])  to form IL-1 active species(17KDa)[3].  The active mature IL-1 cytokines could mediate a large range of biological activities such as innate and adaptive immunity as well as bio-components of the acute phase reaction, including the febrile response, secretion of adrenocorticotropic hormone (ACIH), and the synthesis of [http://en.wikipedia.org/wiki/Acute-phase_protein acute phase proteins].


Line 48: Line 47:


[7] Hou J, '''Design of a superior cytokine antagonist for topical ophthalmic use''',[http://www.pnas.org/content/110/10/3913.full.pdf Proc Natl Acad Sci USA,2013,110,3913-3918.]
[7] Hou J, '''Design of a superior cytokine antagonist for topical ophthalmic use''',[http://www.pnas.org/content/110/10/3913.full.pdf Proc Natl Acad Sci USA,2013,110,3913-3918.]
</StructureSection>